Post by Galleri Test

Cancer doesn't care if you just fell in love. So why would you wait for symptoms when early traces can be found in our blood? The Galleri test can screen for 50+ cancer types² and increases the detection of early-stage cancers, including many without recommended screening.⁴,⁵ Request the test online or through your healthcare provider — and use Galleri Key “EARLY26” to take $150 off* the list price: https://bit.ly/4ecYlSV The Galleri test is available by prescription only. See Important Safety Information: https://bit.ly/3QHmPWo #Galleri #MCED #DetectCancerEarly Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. *Limited time offer valid only for Galleri test orders placed May 26, 2026, through July 28, 2026, 11:59 pm PST. Valid only for Galleri test orders requested online and approved by the GRAIL-contracted independent telemedicine provider. Offer does not confirm your eligibility for the Galleri test. Valid only for one-time use on domestic US Galleri test orders only. Offer valid only for a discount off the Galleri test list price ($949). Offer cannot be: (1) combined or used with any other discount, promotion, special pricing, or payment plan; (2) used to request a credit on a test order placed prior to the offer period; or (3) posted online or on any other publicly available forum. GRAIL reserves the right to change the terms and conditions, substitute an offer of equal or greater value, and end the offer at any time without notice. For Galleri test orders requested online, you must create an account to redeem this offer and enter the code at the “Introduction” stage, where prompted. 1. Schrag D, et al. Lancet. 2023;402(10409):1251-60. 2. Klein EA, et al. Ann Oncol. 2021;32(9):1167-77. 3. Swanton C. NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening [abstract LBA100]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 30; Chicago. https://bit.ly/4alvcDO 4. US Preventive Services Task Force. A, B, and C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://bit.ly/3PAPU7r 5. Karthik V. Giridhar, MD; Charles McDonnell, MD; Dax Kurbegov, MD; et. al. Safety and Performance Results From PATHFINDER 2, a Registrational Study of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population [presentation]. American Society of Clinical Oncology (ASCO) Congress; 2026 May 29-June 2 https://bit.ly/4uZWCHH